Linking a 10-Year Atherosclerotic Cardiovascular Disease Risk Score to New Cardiovascular Events in Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: Insights from the China Health and Retirement Longitudinal Study (CHARLS) - Scorecard - MDSpire

Linking a 10-Year Atherosclerotic Cardiovascular Disease Risk Score to New Cardiovascular Events in Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: Insights from the China Health and Retirement Longitudinal Study (CHARLS)

  • By

  • Zhitong Li

  • Wenxia Ren

  • Xuhui Li

  • Ruixue Duan

  • Linlin Gao

  • Jiaojiao Li

  • Yajing Bai

  • Yuanyuan Yan

  • Angxian Lü

  • Anqi Zhao

  • Shiwei Liu

  • November 14, 2025

  • 0 min

Share

Clinical Scorecard: Linking a 10-Year Atherosclerotic Cardiovascular Disease Risk Score to New Cardiovascular Events in Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: Insights from the China Health and Retirement Longitudinal Study (CHARLS)

At a Glance

CategoryDetail
ConditionCardiovascular-Kidney-Metabolic Syndrome
Key MechanismsIntegration of cardiovascular, renal, and metabolic dysfunction to assess disease risk.
Target PopulationChinese adults aged 45 years and older.
Care SettingNationwide cohort study using CHARLS data.

Key Highlights

  • ASCVD10 year score predicts cardiovascular events in CKM syndrome stages 0-3.
  • Dynamic changes in ASCVD risk scores correlate with clinical outcomes.
  • CHARLS provides a comprehensive dataset for assessing cardiometabolic risk.

Guideline-Based Recommendations

Diagnosis

  • Utilize the ASCVD10 year score for risk stratification in adults.

Management

  • Implement preventive measures based on ASCVD risk categories.

Monitoring & Follow-up

  • Track changes in ASCVD scores over time to assess risk evolution.

Risks

  • Identify individuals with high cumulative ASCVD scores for targeted interventions.

Patient & Prescribing Data

Adults aged 45 years and older in China.

Focus on managing metabolic disorders to reduce CVD risk.

Clinical Best Practices

  • Conduct regular assessments of ASCVD risk factors.
  • Encourage lifestyle modifications to mitigate cardiometabolic risks.
  • Utilize longitudinal data to inform clinical decision-making.

References

Original Source(s)

Related Content